CS
DYN icon

Credit Suisse’s Dyne Therapeutics DYN Stock Holding History

Credit Suisse’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.03M Buy
36,383
+9,525
+35% +$215K ﹤0.01% 2247
2023
Q4 		$357K Sell
26,858
-967
-3% -$9.45K ﹤0.01% 2872
2023
Q3 		$249K Sell
27,825
-5,822
-17% -$62.7K ﹤0.01% 2985
2023
Q2 		$379K Buy
33,647
+9,931
+42% +$117K ﹤0.01% 2918
2023
Q1 		$273K Buy
23,716
+5,323
+29% +$69.1K ﹤0.01% 3029
2022
Q4 		$213K Buy
18,393
+231
+1% +$2.67K ﹤0.01% 3161
2022
Q3 		$231K Buy
18,162
+147
+0.8% +$1.69K ﹤0.01% 3190
2022
Q2 		$124K Buy
18,015
+1,729
+11% +$11.9K ﹤0.01% 3484
2022
Q1 		$156K Sell
16,286
-918
-5% -$7.82K ﹤0.01% 3424
2021
Q4 		$204K Buy
17,204
+3,022
+21% +$42.5K ﹤0.01% 4266
2021
Q3 		$230K Buy
14,182
+3,176
+29% +$56.3K ﹤0.01% 4184
2021
Q2 		$231K Sell
11,006
-85,711
-89% -$1.61M ﹤0.01% 4222
2021
Q1 		$1.5M Buy
96,717
+59,520
+160% +$1.15M ﹤0.01% 3029
2020
Q4 		$781K Buy
37,197
+19,845
+114% +$393K ﹤0.01% 3514
2020
Q3 		$350K Buy
+17,352
New +$381K ﹤0.01% 3567

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's DYN Position: Q1 2024 in Review

Credit Suisse increased its Dyne Therapeutics (DYN) stake by 35% in Q1 2024, buying an estimated $215K and bringing the position to 36,383 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2247.

Credit Suisse first reported a position in DYN in Q3 2020 and has held it in 15 quarters since. The position peaked at $1.5M in Q1 2021. 169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

  • Credit Suisse held 36,383 shares of Dyne Therapeutics worth $1.03M as of Q1 2024.
  • Credit Suisse bought 9,525 Dyne Therapeutics shares in Q1 2024, an estimated $215K.
  • Dyne Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2247 holding.
  • Credit Suisse first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Credit Suisse's Dyne Therapeutics position peaked at $1.5M in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.